Verified email-pattern data for Algomedix, Inc. is currently limited. You can still use the company insights and contact sections below.
Algomedix is an emerging biotechnology company which is using the advances in precision medicine to accelerate drug discovery and development for TRP (Transient Receptor Potential) targeted therapeutics. Critical members of the large TRP superfamily include TRPA1, which is a validated target recognized by the pharmaceutical industry for the discovery and development of novel therapeutics to treat pain, inflammation, ocular and dermatological disease.
Algomedix has successfully identified novel small molecules that target human TRPA1 with both high potency and specificity, and have been optimized to have excellent drug-like properties. Thus, the Algomedix compounds represent a major advance in next-generation pain killers which have no opioid related, NSAID related, or gabapentanoid adverse effects, and have been rationally designed to have no addiction or abuse liabilities. These advantages are further enhanced by a primary peripheral mechanism of action, blocking pain at its source. Algomedix possesses near-term clinical development opportunities combined with novel approaches to developing its first-in-class novel therapeutics addressing a critical unmet medical need.
Algomedix's most advanced patented compound is in late-stage preclinical development and prepared to advance to clinical trials. This compound has demonstrated potent analgesic activity activity in multiple established pain models, which are recognized as the gold standards in the areas of osteoarthritis pain (OA), neuropathic pain, and chemotherapeutic-induced peripheral neuropathy. Due to the critical and fundamental role of TRPA1 in mediating the initial steps of pain signaling throughout the body, there are multiple therapeutic applications for treating chronic and acute pain in patients.
In addition, Algomedix is pursuing programs developing a pipeline of novel, first-in-class molecules for other indications, which include chronic kidney disease and cardiac hypertrophy
Company Details
- Founded
- -
- Address
- 16212 Bothell-Everett Hwy, Suite F280, Mill Creek,washington 98012,united States
- Phone
- 425.379.7900
- Industry
- Biotechnology Research
- Website
- http://www.algomedix.com
- Keywords
- Drug discovery, Pharmaceuticals, Pain, Analgesics, Medicinal chemistry, TRP receptor-channels, Pharmacology, Precision medicine, CKD, Kidney disease, Ion Channels, GPCRs, Assay Development, Clinical, Channelopathy.
- HQ
- MILL CREEK, Washington
Algomedix, Inc. Questions
ALGOMEDIX, INC.'s helpline number is 425.379.7900
ALGOMEDIX, INC.'s website is http://www.algomedix.com
ALGOMEDIX, INC.'s LinkedIn profile is https://www.linkedin.com/company/algomedix-inc.
ALGOMEDIX, INC.'s industry is
Biotechnology Research
ALGOMEDIX, INC.'s top competitors are
Vertex Pharmaceuticals,
Curiouser.ai,
Lumos Pharma,
Synairgen Limited,
Irvine Systems, Inc.,
Ampacet Corporation,
Providence,
Revalia Bio,
Savara Inc.,
Sonoma Biotherapeutics, Inc..
ALGOMEDIX, INC.'s categories are Biotechnology Research
ALGOMEDIX, INC.'s founding year is 2010
Explore related pages
Related company profiles:
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 10 free credits.
Search the #1 Contact Database
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.